Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buntanetap + sildenafil
- Development stage
- Unknown
- Lead developer
- Annovis Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Buntanetap + sildenafil is a small molecule combination therapy being developed by Annovis Bio for the treatment of neurodegenerative diseases, including Alzheimer's disease and dementia. Buntanetap (formerly ANVS401) is an orally administered, brain-penetrant small molecule that inhibits the translation of neurotoxic proteins such as amyloid precursor protein (APP), alpha-synuclein, and tau by binding to the iron-responsive element (IRE) in the 5' untranslated region of their mRNA. Sildenafil, the active ingredient in Viagra, is a phosphodiesterase type 5 (PDE5) inhibitor that has demonstrated neuroprotective potential and the ability to lower neurotoxic tau levels in clinical and preclinical models. Early preclinical data suggests a strong synergistic effect from combining these two agents, potentially restoring cognitive function to healthy levels or improving it beyond normal. The combination is currently in Phase 2 development.
- Brand names
- Viagra
- Other names
- buntanetap + Viagrabuntanetap + sildenafil combination
02
Targets
PDE5 (Phosphodiesterase 5A)TARDBP (TAR DNA-binding protein 43)ACO (Aconitase 1)SNCA (Alpha-synuclein)IRE (Iron-responsive element)MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on buntanetap + sildenafil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buntanetap + sildenafil.